SCHEMBL4091072

SCHEMBL4091072

CS(=O)(=O)c1ncc2cc(-c3ccccc3Cl)c(=O)n(C3CC3)c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 5/20 0.48
NOD2 Q9HC29 5/20 0.48
ACVR1 Q04771 2/20 0.48
LCK P06239 1/20 0.47
MAPK14 Q16539 1/20 0.47
CCND1 P24385 7/20 0.43
CCNE1 P24864 7/20 0.43
CDK2 P24941 7/20 0.43
CDK6 Q00534 7/20 0.43
CCNT1 O60563 1/20 0.43
CDK4 P11802 1/20 0.43
CCND3 P30281 1/20 0.43
CDK9 P50750 1/20 0.43
TNK2 Q07912 3/20 0.43
PAK1 Q13153 1/20 0.42
SIK1 P57059 1/20 0.41
SIK2 Q9H0K1 1/20 0.41
SIK3 Q9Y2K2 1/20 0.41
ABL1 P00519 1/20 0.40
FGFR4 P22455 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766648 0.86 FGFR1 (0.51) RIPK2NOD2ACVR1MAPK14CCND1
SCHEMBL29785435 0.83 PIK3CA (0.51) RIPK2NOD2ACVR1ABL1
SCHEMBL20674135 0.83 PIK3CA (0.51) RIPK2NOD2ACVR1ABL1
SCHEMBL4083936 0.83 RIPK2 (0.65) RIPK2NOD2ACVR1LCKMAPK14
SCHEMBL4147310 0.83 MAPK14 (0.44) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL25123123 0.81 CCNE1 (0.62) CCND1CCNE1CDK2CDK6CCNT1
SCHEMBL30836981 0.81 CCNE1 (0.62) CCND1CCNE1CDK2CDK6CCNT1
SCHEMBL4157046 0.80 DRD2 (0.42) CCND1CCNE1CDK2CDK6CCNT1
SCHEMBL4084205 0.79 CCND1 (0.54) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL28382929 0.79 RIPK2 (0.39) RIPK2NOD2ACVR1LCKMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
WO-2008078249-A1 ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2008-07-03 WO disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 RIPK2 955/4885NOD2 48/4885ACVR1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.